GBL has acquired a co-controlling minority stake in Rayner, partnering with CVC Capital Partners to enhance the company's growth through strategic investments in research, development, and potential acquisitions in the ophthalmic market.

Information on the target

Rayner is a global leader in ophthalmic innovation, renowned for its portfolio of innovative and clinically superior ophthalmic products. Established in 1949 with the development of the world’s first intraocular lens (IOL), Rayner has evolved into a pioneering force in the surgical ophthalmology segment. The company’s offerings include monofocal and premium IOLs, ophthalmic consumables such as OMIDRIA® and Ophteis OVDs, the SOPHI Phaco platform, and a suite of digital tools designed to enhance the convenience for both surgeons and patients. With operations in over 80 countries, Rayner improves the eyesight of more than 3 million patients annually.

Recently, Rayner has made significant investments in research and development, manufacturing, and infrastructure, positioning itself for further expansion. Under the ownership of CVC Capital Partners since 2021, the company has experienced robust growth and is now set to scale its operations further with the support of GBL’s investment.

Industry overview in the target’s specific country

The ophthalmic surgical market is experiencing rapid growth, driven by an aging population and increasing prevalence of eye-related disorders. In the specific country where Rayner operates, the demand for advanced ophthalmic solutions is on the rise, fuel